Wednesday, February 10, 2010, 2:23pm SGT - The Singapore stock market closes in 2 hours and 37 minutes.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Vertex Pharmaceuticals Incorporated (VRTX)

At 5:00AM SGT: 37.90 USD  Up 0.48 (1.28%)  
 MORE ON VRTX 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Vertex Pharmaceuticals Incorpor (NasdaqNM:VRTX) Delayed quote dataEdit
After Hours: 37.42 Down 0.48 (1.27%) as of 6:00am SGT on 02/10/10
Last Trade:37.90 USD
Trade Time:5:00AM SGT
Change:Up 0.48 (1.28%)
Prev Close:37.42
Open:37.78
Bid:N/A
Ask:43.10 x 1200
1y Target Est:42.94
Day's Range:37.33 - 38.36
52wk Range:25.94 - 44.24
Volume:1,208,365
Avg Vol (3m):2,008,970
Market Cap:6.87B
P/E (ttm):N/A
EPS (ttm):-3.82
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add VRTX to Portfolio   Download Data

 HEADLINES 
•New Star Analyst Rankings for Vertex Pharmaceuticals Incorpor
StarMine (Sun, Feb 7)
•Vertex Pharmaceuticals Inc. Q4 2009 Earnings Call Transcript
at Seeking Alpha (Fri, Feb 5)
•[video] Successfactors, Pitney Bowes Announce
at Forbes.com (Fri, Feb 5)
•UPDATE - Vertex 4th quarter loss grows with costs
at Reuters (Fri, Feb 5)
•VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen
EDGAR Online (Fri, Feb 5)
•Vertex Pharmaceuticals Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs
Business Wire (Fri, Feb 5)
•Full Year 2009 Vertex Pharmaceuticals Incorporated Earnings Release - After Market Close
CCBN (Thu, Feb 4)
•Vertex sees positive data in cystic fibrosis study
AP (Thu, Feb 4)
•UPDATE - Vertex cystic fibrosis drug shows promise in trial
at Reuters (Wed, Feb 3)
•Vertex Announces Results from Phase 2a Trial of VX-809 Targeting the Defective Protein Responsible for Cystic Fibrosis
Business Wire (Wed, Feb 3)
More Headlines for VRTX...
 ANALYST 
EPS Est (next year) (Dec-09) :-3.70
EPS Est (in 2 years) (Dec-10) :-3.12
Avg Rec (current)*:2.1
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Vertex Pharmaceuticals Incorporated engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices